Alzheimer’s Drugs Should Be Limited To Moderate Disease, U.K.’s NICE Says
This article was originally published in The Pink Sheet Daily
Executive Summary
National Institute for Health & Clinical Excellence recommends limited use of acetylcholinesterase inhibitors, finds against Namenda.
You may also be interested in...
NICE To Release Final Alzheimer's Guidance Nov. 22
Appeals by industry and the Alzheimer's Society were not granted, the U.K. agency says.
NICE To Release Final Alzheimer's Guidance Nov. 22
Appeals by industry and the Alzheimer's Society were not granted, the U.K. agency says.
NICE To Hear Appeals On Alzheimer’s Appraisal
The U.K. National Institute for Health & Clinical Excellence will hear five appeals against a final appraisal determination that limits recommended National Health Service coverage of four Alzheimer's disease treatments